SciClone Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. Our strategy is to in-license late-stage clinical products and develop them for commercialization in the United States, Europe, and China, one of the world’s fastest growing pharmaceutical markets.

• SciClone’s U.S. and European biotechnology business is focused on developing late-stage products addressing the needs for better therapy for pancreatic cancer, melanoma, and for the difficult to treat hepatitis C virus.

• SciClone China generates growing revenues and important cash flow to fund the expansion of its business, and the development of our worldwide product portfolio.

Our lead product ZADAXIN®, our brand of thymalfasin, is one of the largest selling imported drugs in China today based on revenues, and ZADAXIN also is approved in several other promising international markets. For the U.S. and Europe, we are evaluating thymalfasin in a nearly completed phase 3 trial for the hepatitis C virus (HCV) and a planned phase 3 trial for malignant melanoma. For the U.S., we are conducting a phase 2 HCV trial for SCV-07 and a phase 2 pancreatic cancer trial for RP101.